Aktienanalyse zu Rhythm Pharmaceuticals Inc (RYTM)RYTMRhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company's lead asset, IMCIVREE, is an MC4R agonist designed to treat hyperphagia and severe obesity, is approved by the Food and Drug Administration (FDA) to reduce excess body weight and maintain reduction long term in adults and pediatric patients aged four years and older with acquired hypothalamic obesity, adult and pediatric patients two years of age and older with syndromic or monogenic obesity due to Bardet-Biedl syndrome (BBS) or genetically confirmed pro-opiomelanocortin (POMC), including proprotein convertase subtilisin/kexin type 1 (PCSK1), deficiency or leptin receptor (LEPR) deficiency. In addition to it the Company is advancing a broad clinical development program for setmelanotide in other rare diseases, as well as investigational MC4R agonists bivamelagon and RM-718, and a preclinical suite of small molecules for the treatment of congenital hyperinsulinism. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Rhythm Pharmaceuticals is currently a hold. The stock is priced at $89.27, with a forward P/E ratio of 526.32, indicating high expectations for future earnings, but it also has a negative net income margin of -69.19%. The recent approval of IMCIVREE in Japan and significant revenue growth of 47% year-over-year in Q2 2026 are positive catalysts. However, the high forward P/E and recent insider selling activity (288.14% increase) suggest caution. The main risk is the high forward P/E ratio, which indicates that the market has high expectations for future performance that may not be met.

4 analysts cover RYTM: 3 rate it Buy, 1 Hold and 0 Sell. The average price target is 140.62.